<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511897</url>
  </required_header>
  <id_info>
    <org_study_id>20200420</org_study_id>
    <nct_id>NCT04511897</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of An'Ningpai Expectorant in Non-CF Bronchiectasis</brief_title>
  <official_title>Efficacy and Safety of An'Ningpai Enteric Soft Capsuleson in Stable Non-CF Bronchiectasis With Hypersecretion: a Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess whether the long-term use of oral An'Ningpai&#xD;
      Enteric Soft Capsuleson (300 mg, three times daily, 12 months) might reduce the incidence of&#xD;
      exacerbations and improve the quality of life in patients with Non-CF bronchiectasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucus hypersecretion plays an essential role in bronchiectasis. It has been deduced that&#xD;
      reducing the production of mucus or improving the clearance of sputum in the airway is the&#xD;
      key to break down this &quot;vicious cycle&quot; and enhance the therapeutic efficacy for&#xD;
      bronchiectasis.&#xD;
&#xD;
      The investgators aimed to assess whether the long-term use of oral An'Ningpai Enteric Soft&#xD;
      Capsules (300 mg, three times daily) might reduce the rate of exacerbations and improve the&#xD;
      quality of life in patients with bronchiectasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of acute exacerbation</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first exacerbation</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The volume of 24h sputum</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leicester Cough Questionnaire</measure>
    <time_frame>Six months</time_frame>
    <description>Cough Questionnaire for the degree of cough. The minimum value is 1 and maximum value is 21. Higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of life-Bronchiectasis</measure>
    <time_frame>Six months</time_frame>
    <description>Questionnaire for the life of bronchiectasis. The minimum value is 0 and maximum value is 100; higher scores indicate better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diarrhea</measure>
    <time_frame>Six months</time_frame>
    <description>One of common adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No experimental durgs used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>An'ningpai</intervention_name>
    <description>An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Expectorant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) subjects older than 18 ; 2)a diagnosis of bronchiectasis was according to the 2010&#xD;
        British Thoracic Society guidelines; 3) with hypersecretion ï¼šhigh viscous sputum symptoms&#xD;
        (sputum traits score 2-3 points) ;4) patients had least two exacerbations in the past year&#xD;
        and were in a state for at least 4 weeks prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary&#xD;
        aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis,&#xD;
        etc.); 2)primary diagnosis of COPD or asthma; 3)a history of severe cardiovascular disease;&#xD;
        4)comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or&#xD;
        intestinal malabsorption; 5)a known allergy to Eucalyptol , Limonene and Pinene Enteric&#xD;
        Soft Capsules; 6)pregnancy or lactation (for women);7)a history of prior macrolide use of&#xD;
        more than 1 week; 8)and poor compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-fu Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-fu Xu, MD</last_name>
    <phone>+86 13321922898</phone>
    <email>jfxucn@163.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Chief of Department of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Brochiectasis Adult</keyword>
  <keyword>Hypersecretion</keyword>
  <keyword>Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Expectorants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

